- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
little upside
Recs
I think that OPK has alot of potential to the upside. It is trying to establish a foothold in a great industry and has made some aquisitions that will help in the near ftrure. I would buy this and hold to see if other investors have the same thoughts.
Recs
jim cramer long term one year should hit a billion in revenues
Recs
Recs
OPKO health is a pure play on Dr. Philip Frost and his ability to create companies in this sector and then sell them for large shareholder gains. Dr. Frost also continues to be a buyer in the M+A world of little known company's that fit into what he is trying to accomplish.
My gut tells me to never bet against self made men like Dr. Philip Frost and I'm going to ride his coat tails this time. He obviously believes in what he is doing as he has continually purchases shares in this company, over the counter, for the last 2 years.
Recs
I see a lot of speculation here about a buyout, but let's get back to reality. It doesn't seem likely that any company will pay over $2 billion for just $170 million in net assets and less than $40 million in annual revenue. Opko goes from a measly $5-$6 million in quarterly revenue to $11 and all of a sudden its the best company ever? Look closer and you'll see that a near doubling in revenue resulted in an even larger loss than last year!
Recs
pipeline of novel in house testing for doctors
Recs
CEO is genius billionaire making a the right moves
Recs
It will snapped up by one of the big pharmas
Recs
Insiders buying on insider insight on insider information. Three good reasons to buy now.
Recs
CEO is buying a ton of shares, so I'm initiating this to see what happens.
Recs
Nice technicals, and management!
Recs
All Health stocks are going to do well as baby boomers all retire and government fans the flames of health care.
Recs
barely any revenue & no product forthcoming (2-3 years) does not equal a $1.4bn market cap.
Recs
i think they are creating turbulence by insider trading
Recs
Stock is undervalued relative to the comps. Market is just a little slow to realize it. Comps in Biotech averaging $5B market cap.
Recs
Heaving insider purchase.
Recs
This little biotech play has been steadly moving in the right direction for some time. Don't miss out. They have a solid BOD.
Recs
Covestor Model Manager William Smith sold OPK in his Price Volatility Volume Covestor Model ( http://covestor.com/William-Smith )
Recs
OPK has a too high valuation compared to its sales potential. It is also loss making. Its stock price may be more than halved.
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 31 : 1 2 Next »